IDEXX Laboratories, Inc. $IDXX Shares Sold by Ritholtz Wealth Management

Ritholtz Wealth Management trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 16.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,305 shares of the company’s stock after selling 1,061 shares during the period. Ritholtz Wealth Management’s holdings in IDEXX Laboratories were worth $2,770,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. UNIVEST FINANCIAL Corp grew its holdings in shares of IDEXX Laboratories by 3.5% in the 3rd quarter. UNIVEST FINANCIAL Corp now owns 8,358 shares of the company’s stock worth $4,364,000 after purchasing an additional 282 shares during the last quarter. Jacobi Capital Management LLC acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $191,000. Jefferies Financial Group Inc. increased its position in shares of IDEXX Laboratories by 659.7% during the 3rd quarter. Jefferies Financial Group Inc. now owns 11,380 shares of the company’s stock worth $5,943,000 after purchasing an additional 9,882 shares in the last quarter. First Command Advisory Services Inc. lifted its holdings in IDEXX Laboratories by 36.8% during the 3rd quarter. First Command Advisory Services Inc. now owns 364 shares of the company’s stock valued at $190,000 after purchasing an additional 98 shares during the last quarter. Finally, 71 West Capital Partners lifted its holdings in IDEXX Laboratories by 11.9% during the 3rd quarter. 71 West Capital Partners now owns 1,288 shares of the company’s stock valued at $673,000 after purchasing an additional 137 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $704.23 on Monday. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The stock has a market capitalization of $55.48 billion, a PE ratio of 47.49 and a beta of 1.55. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.88 and a current ratio of 1.19. The stock’s fifty day moving average is $562.41 and its 200-day moving average is $573.52.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business posted $3.22 earnings per share. Equities research analysts expect that IDEXX Laboratories, Inc. will post 15.05 EPS for the current fiscal year.

Insider Activity

In other IDEXX Laboratories news, Director Daniel M. Junius sold 1,200 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $704.07, for a total value of $844,884.00. Following the completion of the transaction, the director directly owned 2,361 shares of the company’s stock, valued at approximately $1,662,309.27. The trade was a 33.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sharon E. Underberg sold 8,906 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total transaction of $6,132,582.54. Following the transaction, the executive vice president owned 7,169 shares in the company, valued at $4,936,501.71. The trade was a 55.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 41,428 shares of company stock worth $28,567,934. 0.79% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on IDXX. JPMorgan Chase & Co. reduced their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research report on Friday, October 16th. Barclays dropped their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. UBS Group lifted their target price on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research note on Tuesday, November 3rd. Citigroup lifted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Finally, The Goldman Sachs Group assumed coverage on IDEXX Laboratories in a report on Friday, October 16th. They issued a “buy” rating and a $740.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $717.27.

Read Our Latest Analysis on IDXX

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

See Also

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.